Fondazione Policlinico Gemelli IRCCS
Roma, Italy
Location contact
cammertoni federico
CONTACT
serena d'avino
CONTACT
NCT Number: NCT06471062
Transit-time flowmetry (TTFM) allows grafts quality control during coronary artery bypass surgery by measuring the flow volume through them.
To date, many studies have deeply studied the predictive role on the graft outcomes of the various flowmetry-derived parameters. One of the least investigated aspects, however, is the mutual influence that two newly realized grafts can have. This possibility would be related to the presence of a more or less developed collateral circulation between the bypassed territories.
The purpose of this study is to assess whether a graft for a territory different than that provided by the left anterior descending artery (LAD) may affect the functionality (measured through flowmetry) of the left internal mammary artery - LAD graft.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Roma, Italy
cammertoni federico
CONTACT
serena d'avino
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: During the surgery, out of cardiopulmonary bypass
The primary aim of this study is to assess whether a graft for a non-LAD coronary target modifies the performance (measured by flowmetry) of the flow in the LIMA>LAD graft.
PI is expressed by the ratio of the flow volume amplitude and mean flow volume, both quantified by a flowmeter (ml/min / ml/min). An ideal value would be < 3
Time frame: During surgery, before and after transient occlusion of the other grafts for non-LAD coronary targets
under rest conditions and after pharmacological stress. The unit of measure will be ml/min. The average flow should be above 20 ml/min.
Time frame: During surgery,before and after transient occlusion of the other grafts for non-LAD coronary targets.
under rest conditions and after pharmacological stress. The unit of measure will be the ratio between two parameters expressed by ml/min.
Time frame: During surgery,before and after transient occlusion of the other grafts for non-LAD coronary targets.
depending on its dominance or hyperdominance. The unit of measure will be the ratio between two parameters expressed by ml/min. DF% is accepted around 50%.
Time frame: During surgery, before and after transient occlusion of the other grafts for non-LAD coronary targets.
under rest conditions and after pharmacological stress. The unit of measure will be the ratio between two parameters expressed by ml/min. The identified cut-off is 3% of the total flow.
Time frame: During surgery, before and after transient occlusion of the LIMA>LAD graft
under rest conditions and after pharmacological stress. The meaf low will be measured in "ml/min". The others will be expressed by the ratio between two parameters expressed by ml/min.
Contact information is provided by the study sponsor or research team.
cammertoni federico
CONTACT
serena davino
CONTACT
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Other
Transit Time Flow Measurement in Coronary Surgery: The Mutual Influence of Collateral Flow Between Different Coronary Territories on Parameter Metrics
Acronym: COLLATERAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07239921
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT06348875
Angina Pectoris, Arterial Occlusive Diseases
Grand Rapids, Michigan, United States
View Trial DetailsNCT06565793
Angina Pectoris, Angina, Unstable
View Trial DetailsNCT05782738
Arterial Occlusive Diseases, Arteriosclerosis
Cirié, Tori O, Italy
View Trial Details